Disease · MONDO_0011849
Comparisons in its trials105
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 105
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Risankizumab vs Placebo: deaths from any cause | 1 of 483 | 0 of 481 | 964 | NCT03675308 | Trial comparisons |
| Risankizumab vs Placebo: serious adverse events | 12 of 483 | 18 of 481 | 964 | NCT03675308 | Trial comparisons |
| Etanercept BIW/QW vs Etanercept QW/QW: Number of Patients Achieving Clear or Almost Clear on Physician Global Assessment (PGA) of Psoriasis | 176 of 379 | 119 of 373 | 752 | NCT00245960 | Trial comparisons |
| Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone: serious adverse events | 15 of 364 | 16 of 366 | 730 | NCT00574249 | Trial comparisons |
| Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16 | 169 of 312 | 123 of 312 | 624 | NCT04908189 | Trial comparisons |
| Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16 | 90 of 312 | 51 of 312 | 624 | NCT04908189 | Trial comparisons |
| Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16 | 33 of 312 | 17 of 312 | 624 | NCT04908189 | Trial comparisons |
| Deucravacitinib vs Placebo: Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16 | 80 of 312 | 46 of 312 | 624 | NCT04908189 | Trial comparisons |
| Ixekizumab vs Adalimumab: Number of Participants Who Answered Yes to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS) | 9 of 283 | 7 of 283 | 566 | NCT03151551 | Trial comparisons |
| AIN457 6 mg/kg - 3 mg/kg i.v vs Placebo up to Week 16: deaths from any cause | 0 of 374 | 1 of 190 | 564 | NCT04209205 | Trial comparisons |
| AIN457 6 mg/kg - 3 mg/kg i.v vs Placebo up to Week 16: serious adverse events | 22 of 374 | 4 of 190 | 564 | NCT04209205 | Trial comparisons |
| Deucravacitinib vs Placebo: Number of Participants Who Achieve a Clinically Meaningful Improvement in HAQ-DI Score at Week 16 | 131 of 268 | 118 of 273 | 541 | NCT04908189 | Trial comparisons |
| Risankizumab 150 mg vs Placebo: deaths from any cause | 0 of 224 | 0 of 219 | 443 | NCT03671148 | Trial comparisons |
| Risankizumab 150 mg vs Placebo: serious adverse events | 9 of 224 | 12 of 219 | 443 | NCT03671148 | Trial comparisons |
| Bimekizumab 160mg vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 108 of 267 | 44 of 132 | 399 | NCT03896581 | Trial comparisons |
| Bimekizumab 160mg vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study | 2 of 267 | 0 of 132 | 399 | NCT03896581 | Trial comparisons |
| Bimekizumab 160mg vs Placebo: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study | 5 of 267 | 0 of 132 | 399 | NCT03896581 | Trial comparisons |
| Bimekizumab 160mg vs Placebo: deaths from any cause | 0 of 267 | 0 of 132 | 399 | NCT03896581 | Trial comparisons |
| Bimekizumab 160mg vs Placebo: serious adverse events | 5 of 267 | 0 of 132 | 399 | NCT03896581 | Trial comparisons |
| Secukinumab 150mg vs Secukinumab 300mg: Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation) | 94 of 112 | 235 of 254 | 366 | NCT03066609 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011849/comparisons